SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Exelixis headquarters/Company courtesy
Drug Development
Roche, Exelixis Score Phase III Prostate Cancer Win for Cabometyx-Tecentriq Combo
In the CONTACT-02 pivotal trial, the combination of Exelixis’ Cabometyx and Roche’s Tecentriq reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer.
January 25, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: FDA sign at Washington D.C. headquarters
Policy
Gilead’s Tecartus Gets Slight Reprieve on FDA List of CAR-T Boxed Warnings
While the FDA considers a T cell malignancy risk to be applicable to all commercial CAR-T therapies, Gilead Sciences’ Tecartus has a revised warning that potential adverse events “may” occur.
January 24, 2024
 · 
2 min read
 · 
Tyler Patchen
Courtesy of Ionis Pharmaceuticals
Drug Development
Ionis Touts Positive Topline Phase III Results for HAE Drug, Plans NDA
The company said it’s preparing to file a New Drug Application with the FDA on the strength of late-stage study data for its investigational RNA-targeted donidalorsen in patients with hereditary angioedema.
January 24, 2024
 · 
2 min read
 · 
Tyler Patchen
Deals
Grab an umbrella, it’s raining ⁠IPOs⁠!
This week, Lori, Greg and Tyler discuss the first ⁠surge of IPO activity⁠ this year plus gene therapy pricing,
January 23, 2024
 · 
1 min read
 · 
Lori Ellis
Facade of Novo Nordisk's office in Fremont, California
Drug Development
Novo Nordisk Inks Potential $255M Deal with EraCal, Targets Another Obesity Asset
The Danish pharma has signed a collaboration and license agreement with Swiss biotech EraCal Therapeutics to access a novel candidate for controlling appetite and body weight.
January 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Roche's tower in Shanghai, China
Business
Roche Ends Longstanding Collaboration with AC Immune, Hands Back Assets
After showing some unfavorable results for its data, AC Immune on Monday announced it will be getting back its Alzheimer’s disease candidates from Roche’s Genentech.
January 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Sanofi Distribution Center
Deals
Sanofi Buys Inhibrx for Up to $2.2B to Bolster Inflammation Drug Pipeline
The French drugmaker is buying California-based biotech Inhibrx to gain access to its clinical-stage drug candidate for alpha-1 antitrypsin deficiency, as it tries winning over investors with potential blockbusters.
January 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Gilead's corporate headquarters in Silicon Valley
Drug Development
Gilead’s ADC Trodelvy Fails Phase III NSCLC Study, Stock Drops 10%
Amid a hot antibody-drug conjugate market in oncology, Gilead Sciences announced Monday that its ADC Trodelvy did not reach a primary endpoint in a non-small cell lung cancer trial.
January 22, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Nasdaq signage and building in New York City
Deals
ArriVent Biopharma Seeks to Net Over $156M Potentially in IPO
With initial public offering activity continuing to gain momentum in early 2024, ArriVent Biopharma in a Monday SEC filing laid out the company’s plans to go public.
January 22, 2024
 · 
2 min read
 · 
Tyler Patchen
Policy
Ex-Pfizer Employee Convicted of Insider Trading Related to Paxlovid Data
Amit Dagar, a former Pfizer employee, was found guilty of insider trading by a federal jury in New York involving clinical trial results for COVID-19 antiviral Paxlovid that he profited from.
January 19, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pile of money/iStock, Ihor Lukianenko
BridgeBio Secures $1.25B in Financing, Prepares for Potential Product Launch
The funding includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis to treat transthyretin amyloid cardiomyopathy.
January 19, 2024
 · 
1 min read
 · 
Tyler Patchen
Pablo Monsalve / VIEWpress
Deals
CG Oncology Sets IPO Target, Looks to Raise Up to $209M
The bladder cancer-focused biotech is looking to be one of the first companies out of the gate with an initial public offering in 2024.
January 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A line of vials to hold injectable medic
Deals
CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M
Taiwanese contract development and manufacturing organization Bora will purchase Minnesota-based Upsher-Smith Laboratories, expanding operations into the U.S. for the first time.
January 18, 2024
 · 
2 min read
 · 
Tyler Patchen
3d render of cytotoxic CAR exosomes secreted by engineered T immune cells
Business
Cell Therapy Startup Tr1X Emerges from Stealth with $75M Series A
The San Diego-based startup, specializing in allogeneic engineered Treg and CAR-Treg cell therapies, plans to be in Phase I clinical trials in multiple indications in 2024.
January 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Drug Development
Optimistic, but for how long? Our big takeaways from #JPM2024
The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco during JPM 2024.
January 17, 2024
 · 
1 min read
 · 
Lori Ellis
Load More